Ocugen, Inc. 8-K

What Happened

• On May 4, 2026, Ocugen, Inc. announced an intended private placement of $115 million aggregate principal amount of convertible senior notes due 2034 (the “Notes”) to qualified institutional buyers under Rule 144A. The company also furnished excerpts from a preliminary offering memorandum that include preliminary unaudited financial information as of March 31, 2026.
• The 8-K and attached materials note the offering is subject to market conditions and may not be completed on the stated terms; the preliminary financials have not been audited and may change.

Key Details

• Offering size: $115.0 million aggregate principal amount of convertible senior notes due 2034.
• Overallotment option: initial purchaser may be granted an option to buy up to an additional $15.0 million of Notes for settlement within 13 days of initial issuance.
• Use of proceeds: approximately $32.7 million of net proceeds expected to fully repay outstanding principal, accrued interest and related fees under the Avenue Loan Agreement and terminate that loan; remaining net proceeds for general corporate purposes.
• Disclosure items: Exhibit 99.1 includes preliminary unaudited financial info as of March 31, 2026; Exhibit 99.2 is the press release. The filing reiterates forward-looking statement risks and that neither the 8-K nor the release is an offer to sell securities.

Why It Matters

• Debt reduction: the company plans to use part of the proceeds to repay and terminate its Avenue loan, which reduces near-term debt obligations.
• Potential dilution and market effects: convertible notes can dilute equity upon conversion and the filing warns market conditions and conversion terms may affect the company’s stock and investors. The offering is not guaranteed to close and preliminary financials are unaudited, so investors should treat the disclosed figures as estimates.